Senti Biosciences Management
Management criteria checks 2/4
Senti Biosciences' CEO is Tim Lu, appointed in Jul 2016, has a tenure of 8.58 years. total yearly compensation is $930.69K, comprised of 66.5% salary and 33.5% bonuses, including company stock and options. directly owns 3.52% of the company’s shares, worth $704.69K. The average tenure of the management team and the board of directors is 0.8 years and 3.5 years respectively.
Key information
Tim Lu
Chief executive officer
US$930.7k
Total compensation
| CEO salary percentage | 66.5% |
| CEO tenure | 8.6yrs |
| CEO ownership | 3.5% |
| Management average tenure | less than a year |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Dec 28
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?
Sep 27Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform
Sep 22Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M
Aug 16Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Jun 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$71m |
| Jun 30 2024 | n/a | n/a | -US$79m |
| Mar 31 2024 | n/a | n/a | -US$82m |
| Dec 31 2023 | US$2m | US$607k | -US$83m |
| Sep 30 2023 | n/a | n/a | -US$80m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$811k | US$538k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$24m | US$475k | -US$55m |
Compensation vs Market: Tim's total compensation ($USD930.69K) is above average for companies of similar size in the US market ($USD640.92K).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
CEO
Tim Lu (42 yo)
8.6yrs
Tenure
US$930,689
Compensation
Dr. Timothy K. Lu, also known as Tim, Ph D., M.D., is Member of Scientific Advisory Board of Integrated Biosciences, Inc. He served as Member of Scientific Advisory Board at Absci Corporation since Februar...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.6yrs | US$930.69k | 3.52% $ 704.7k | |
| President | less than a year | US$627.71k | 0% $ 0 | |
| Scientific Co-Founder | no data | US$58.72k | 0.38% $ 76.8k | |
| Interim CFO | less than a year | US$547.54k | no data | |
| Scientific Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Senior VP & Head of Legal Affairs | less than a year | no data | no data | |
| Vice President of Strategic Finance & Corporate Development | 1.1yrs | no data | no data | |
| VP of People & Culture Strategy & Head of Administrative Operations | less than a year | no data | no data |
0.8yrs
Average Tenure
56yo
Average Age
Experienced Management: SNTI's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.7yrs | US$930.69k | 3.52% $ 704.7k | |
| Scientific Co-Founder | 3.5yrs | US$58.72k | 0.38% $ 76.8k | |
| Scientific Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.5yrs | no data | no data | |
| Independent Director | 8.6yrs | US$71.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$64.85k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | US$64.61k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.5yrs | no data | no data |
3.5yrs
Average Tenure
58yo
Average Age
Experienced Board: SNTI's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:35 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Senti Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Lut Ming Cheng | J.P. Morgan |